Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
gene therapy
life sciences
novartis
zolgensma
3
×
biogen
boston blog main
clinical trials
drug prices
drug pricing
generic drugs
national
national blog main
national top stories
new york top stories
san francisco top stories
spinal muscular atrophy
abbvie
adalimumab (humira)
aducanumab
aduro biotech
affordable care act
alez azar
alzheimer's disease
antibiotics
axial spondyloarthritis
bausch health
billy dunn
bioinnovation capital
biolabs
boston
boston top stories
boston university
boulder/denver blog main
boulder/denver top stories
bristol-myers squibb
cancer
cancer immunotherapy
car-t immunotherapy
cell therapy
What
drug
3
×
new
approval
approved
atrophy
bio
biogen’s
biopharmaceutical
biotech
companies
convo
daily
driving
earlier
evrysdi
failures
fda
friday
good
green
healthcare
history
home
improved
industry
innovation
innovations
intended
investment
life
lights
liquid
littered
long
medical
medicine
muscular
nash
news
oral
Language
unset
Current search:
zolgensma
×
drug
×
@xconomy.com
3 years ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com
4 years ago
Drug Pricing: Innovation, Investment, and the Public Good
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
